Dr. Perl studies oncogenic signal transduction in acute myelogenous leukemia. His research focuses upon the phosphotidyl inositol 3' kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway as well as the Fms-like Tyrosine Kinase 3 (FLT3). He has designed and performed clinical trials examining the strategy of inhibiting mTOR to promote chemotherapy response in AML as well as FLT3 inhibitors to treat patients with kinase activating FLT3 mutations. Laboratory correlation science on these studies was also performed by Dr. Perl, leading to improved methods for measuring mTOR activation in clinical samples via phospho-specific flow cytometry of fixed, unfractionated blood and marrow. Dr. Perl is currently exploring the use of flow cytometry for pharmacodynamic monitoring of signal transduction inhibitor response in hematologic malignancies as well as preclinical drug screening in cellular and murine xenotransplantation models.